Skip to main content
SpringerLink
Log in

Single-Domain Antibodies Used to Pretreat the Human Urinary Proteome in Cancer Biomarker Testing

  • METHODS
  • Published:
Molecular Biology Aims and scope Submit manuscript

Abstract

A number of single-domain antibodies (nanobodies) obtained previously to major marker blood proteins were tested as tools to preprocess urine samples from patients with bladder cancer. Nanobody-based tools demonstrated unique possibilities for noninvasive diagnostic studies along with other conventional methods, such as electrophoresis and, in prospect, mass spectrometric analysis. A testing of 22 samples from bladder cancer patients showed that the development of bladder cancer is accompanied by an increase in the urine contents of major blood proteins, including those known as potential bladder cancer biomarkers. New nanobody-based immunosorbents allow both specific enrichment and specific removal of particular antigenic proteins and subproteomes associated with them from a biological fluid. The isolation of immune complexes from the urine of a particular patient is of particular interest. An initial study of the complexes showed not only increased contents of IgA and IgG at advanced stages of the disease, but also many other components, which provide potential biomarkers of the pathological process in a particular patient. It is intended to use the approaches proposed in this work in a future larger-scale study of urine samples from patients with bladder cancer at different stages of the disease in order to identify new promising biomarkers of bladder cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.
Fig. 3.
Fig. 4.
Fig. 5.
Fig. 6.
Fig. 7.

Similar content being viewed by others

REFERENCES

  1. IARC. 2021. Cancer Today. Estimated number of new cases in 2020, worldwide, both sexes, all ages. https://gco.iarc.fr/today/online-analysis-table.

  2. https://uroweb.org/guideline/non-muscle-invasive-bladder-cancer/#3

  3. American Cancer Society. 2020. What is bladder cancer? (https://www.cancer.org/cancer/bladder-cancer/ about/what-is-bladder-cancer.html. Accessed September 2020.

  4. van Rhijn B.W., Burger M., Lotan Y., Solsona E., Stief C.G., Sylvester R.J., Witjes J.A., Zlotta A.R. 2009. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur. Urol. 56 (3), 430‒442. https://doi.org/10.1016/j.eururo.2009.06.028

    Article  PubMed  Google Scholar 

  5. Humphrey P.A., Moch H., Cubilla A.L., Ulbright T.M., Reuter V.E. 2016. The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours. Eur. Urol. 70 (1), 106‒119.

    Article  Google Scholar 

  6. Santoni G., Morelli M.B., Amantini C. Battelli N. 2018. Urinary markers in bladder cancer: an update. Front. Oncol. 7 (8), 362.

    Article  Google Scholar 

  7. Blick C.G.T., Nazir S.A., Mallett S., Turney B.W., Onwu N.N., Roberts I.S.D., Jeremy P. Crew J.H., Cowan N.C. 2011. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic. BJU Int. 110, 84–94.

    Article  Google Scholar 

  8. Tillib S.V., Ivanova T.I., Vasilev L.A. 2010. Fingerprint analysis of “nanoantibody” selection by phage display using two variants of helper phages. Acta Nat. 2, 100–108.

    Google Scholar 

  9. Tillib S., Ivanova T.I., Vasilev L.A., Rutovskaya M.V., Saakyan S.A., Gribova I.Y., Tutykhina I.L., Sedova E.S., Lysenko A.A., Shmarov M.M., Logunov D.Y., Naroditsky B.S., Gintsburg A.L. 2013. Formatted single-domain antibodies can protect mice against infection with influenza virus (H5N2). Antiviral Res. 97, 245‒254.

    Article  CAS  Google Scholar 

  10. Tillib S.V., Privezentseva M.E., Ivanova T.I., Efimov G.A., Gursky Y.G., Georgiev G.P., Goldman I.L., Sadchikova E.R. 2014. Single-domain antibody-based ligands for immunoaffinity separation of recombinant human lactoferrin from the goat lactoferrin of trasgenic goat milk. J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 949–950, 48–57.

    Article  Google Scholar 

  11. Tillib S.V., Vyatchanin A.S., Muildermans S. 2014. Molecular analysis of heavy chain-only antibodies of Camelus bactrianus. Biochemistry (Moscow). 79, 1382–1390.

    Article  CAS  Google Scholar 

  12. Goryainova O.S., Ivanova T.I., Rutovskaya M.V., Tillib S.V. 2017. A method for the parallel and sequential generation of single-domain antibodies for the proteomic analysis of human blood plasma. Mol. Biol. (Moscow). 51 (6), 855–864.

    Article  CAS  Google Scholar 

  13. Tillib S.V. 2020. Prospective applications of single-domain antibodies in biomedicine. Mol. Biol. (Moscow). 54 (3), 317–326.

    Article  CAS  Google Scholar 

  14. Tillib S.V., Ivanova T.I., Lysyuk E.Yu., Larin S.S., Kibardin A.V., Korobko E.V., Vikhreva P.N., Gnuchev N.V., Georgiev G.P., Korobko I.V. 2012. Nanoantibodies for detection and blocking of bioactivity of human vascular endothelial growth factor A(165). Biochemistry (Moscow). 77, 659–665.

    Article  CAS  Google Scholar 

  15. Garas M.N., Tillib S.V., Zubkova O.V., Rogozhin V.N., Ivanova T.I., Vasil’ev L.A., Logunov D.Yu., Shmarov M.M., Tutykhina I.L., Esmagambetov I.B., Gribova I.Yu., Bandelyuk A.S., Naroditsky B.S., Gintsburg A.L. 2014. Target-specific gene delivery using recombinant pseudoadenoviral particles capable of efficiently binding to nanoantibodies. Acta Nat. 6 (2), 102‒113.

    Article  Google Scholar 

  16. Marshall T., Williams K.M. 1998. Clinical analysis of human urinary proteins using high resolution electrophoretic methods. Electrophoresis. 19, 1752‒1770.

    Article  CAS  Google Scholar 

  17. Wessel D., Fluegge U.I. 1984. A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal. Biochem, 138, 141‒143.

    Article  CAS  Google Scholar 

  18. Laemmli U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227, 680‒685.

    Article  CAS  Google Scholar 

  19. Floege J., Boddeker M., Stolte H., Koch K.M. 1990. Urinary IgA, secretory IgA and secretory component in women with recurrent urinary tract infections. Nephron. 56, 50‒55.

    Article  CAS  Google Scholar 

  20. Machii R., Kubota R., Hiratsuka N., Sugimoto K., Masudo R., Kurihara Y., Kobayashi S., Shiba K. 2004. Urinary protein fraction in healthy subjects using cellulose acetate membrane electrophoresis followed by colloidal silver staining. J. Clin. Lab. Anal. 18, 231–236.

    Article  CAS  Google Scholar 

  21. Huang C., Ren J., Ji F., Muyldermans S., Jia L. 2020. Nanobody-based high-performance immunosorbent for selective beta 2-microglobulin purification from blood. Acta Biomater. 107, 232–241.

    Article  CAS  Google Scholar 

  22. Betkerur V., Baumgartner G., Talluri K., Sharifi R., Nagubadi S., Guinan P. 1981. Urinary immunoglobulin A in the diagnosis of bladder cancer. J. Surg. Oncol. 16, 215‒217.

    Article  CAS  Google Scholar 

  23. Khalifa A., Fathi O., Mousa M.A., el Magraby H. 1987. Immunoglobulin A and alpha 2-macroglobulin as tumor markers in bladder cancer. Chemioter. 6 (Suppl. 2), 736‒737.

    CAS  Google Scholar 

  24. Li C., Li H., Zhang T., Li J., Liu L., Chang J. 2014. Discovery of Apo-A1 as a potential bladder cancer biomarker by urine proteomics and analysis. Biochem. Biophys. Res. Commun. 446, 1047‒1052.

    Article  CAS  Google Scholar 

  25. Dong F., Shen Y., Xu T., Wang X., Gao F., Zhong S., Chen S., Shen Z. 2018. Effectiveness of urine fibronectin as a non-invasive diagnostic biomarker in bladder cancer patients: a systematic review and meta-analysis. World J. Surg. Oncol. 16, 61.

    Article  Google Scholar 

  26. Matsumura E., Kosuge N., Nakanishi S., Suda T., Sugawa A., Fujimura T., Miyagi R., Yoshimi N., Saito S. 2020. Urine lactoferrin as a potential biomarker reflecting the degree of malignancy in urothelial carcinoma of the bladder. Tohoku J. Exp. Med. 252 (3), 225‒244.

    Article  CAS  Google Scholar 

Download references

Funding

This work was supported by the Russian Science Foundation (project no. 20-14-00305).

Author information

Authors and Affiliations

  1. Institute of Gene Biology, Russian Academy of Sciences, 119334, Moscow, Russia

    S. V. Tillib, O. S. Goryainova, A. M. Sachko, T. I. Ivanova, N. V. Vorob’ev & P. V. Shegay

  2. Tsyb Medical Radiological Research Center, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 249036, Obninsk, Kaluga oblast, Russia

    T. I. Ivanova

  3. Institute of Medicine, Peoples’ Friendship University of Russia, 117198, Moscow, Russia

    M. Ya. Gaas

  4. Hertsen Moscow Oncology Research Institute, National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 125284, Moscow, Russia

    N. V. Vorob’ev

  5. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, 119991, Moscow, Russia

    N. V. Vorob’ev

  6. National Medical Radiology Research Center, Ministry of Health of the Russian Federation, 125284, Moscow, Russia

    A. D. Kaprin & P. V. Shegay

Authors
  1. S. V. Tillib
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O. S. Goryainova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. M. Sachko
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. T. I. Ivanova
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Ya. Gaas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. V. Vorob’ev
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. D. Kaprin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. V. Shegay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. V. Tillib.

Ethics declarations

Conflict of interests. The authors declare that they have no conflict of interest.

Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies of biological fluids were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants involved in the study. The study was approved by the Ethics Committee at the Institute of Gene Biology (Approval dated January 18, 2021) and the Ethics Committee at the Hertsen Moscow Oncology Research Institute.

Additional information

Translated by T. Tkacheva

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tillib, S.V., Goryainova, O.S., Sachko, A.M. et al. Single-Domain Antibodies Used to Pretreat the Human Urinary Proteome in Cancer Biomarker Testing. Mol Biol 56, 616–627 (2022). https://doi.org/10.1134/S0026893322040124

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S0026893322040124

Keywords:

Search

Navigation